Huang Jeffrey, Schisler John, Wong Hing C, Rosser Charles J, Sterbis Joseph
University of Hawaii Cancer Center, Clinical & Translational Research Program, Honolulu, HI, 96813, USA.
Tripler Army Medical Center, Department of Urology, Honolulu, HI, 96859, USA.
Urol Case Rep. 2017 Jun 8;14:15-17. doi: 10.1016/j.eucr.2017.04.015. eCollection 2017 Sep.
The administration of intravesical chemotherapy or BCG often can prolong the progression-free interval after initial transurethral resection in select bladder cancer (BCa) patients. However, 60% of these patients will recur and up to 30% of patients with recurrent BCa will progress and succumb to their disease over a 15 year period, while another 50% will cystectomy in an attempt to control their disease. Thus better therapeutic strategies are needed for patients who have failed intravesical therapy. In this article, we report the treatment of a 91-year-old man with NMIBC with high-risk features that had failed multiple intravesical therapies.
对于部分膀胱癌（BCa）患者，膀胱内化疗或卡介苗（BCG）灌注通常可延长经尿道初次切除术后的无进展生存期。然而，这些患者中有60%会复发，在15年的时间里，高达30%的复发性BCa患者会病情进展并最终死于该疾病，另有50%的患者会接受膀胱切除术以控制病情。因此，对于膀胱内治疗失败的患者，需要更好的治疗策略。在本文中，我们报告了一名91岁非肌层浸润性膀胱癌（NMIBC）男性患者的治疗情况，该患者具有高风险特征且多种膀胱内治疗均失败。
